Metalloproteinases and their inhibitors—diagnostic and therapeutic opportunities in orthopedics

Björn Pasternak¹,² and Per Aspenberg¹

¹Orthopaedics and Sports Medicine, IKE, Linköping University, Linköping; ²Malmö University Hospital, Malmö, Sweden

Enzymes in control of the extracellular matrix

Matrix metalloproteinases (MMPs) and related enzymes (ADAMs, ADAMTS) and their inhibitors control matrix turnover and function. Recent advances in our understanding of musculoskeletal conditions such as tendinopathy, arthritis, Dupuytren’s disease, degenerative disc disease, and bone and soft tissue healing suggest that MMPs have prominent roles. Importantly, MMPs are amenable to inhibition by cheap, safe, and widely available drugs such as the tetracycline antibiotics and the bisphosphonates. This indicates that these MMP inhibitors, if proven effective for any novel indication, may be quickly brought into clinical practice.

Tissue-degrading enzymes of the metalloproteinase family have been implicated in the pathogenesis of several conditions involving the extracellular matrix. The family includes the matrix metalloproteinases (MMPs), their close relatives “a disintegrin and metalloproteinase” (ADAM), and “a disintegrin and metalloproteinase with thrombospondin motifs” (ADAMTS). MMPs are promising drug targets, and they are amenable to pharmacological inhibition by common clinically available drugs such as tetracyclines and bisphosphonates. A better understanding of the roles of metalloproteinases in tissue injury and the effects of their inhibition has the potential to improve outcome after injury and surgery. Additionally, metalloproteinases have diagnostic potential as markers to predict outcome of disease processes and healing, and to direct tailored therapy.

There has only been one published overview of the role of MMPs in orthopedics (Bramono et al. 2004), covering mostly arthritis. We extend the scope of that review by adding data from reports published in recent years and include a discussion on the ADAMs and ADAMTS, as well as conditions such as tendinopathy, Dupuytren’s contracture, bone and soft tissue healing, and prosthetic loosening.
While most MMPs are secreted into the extracellular space immediately after synthesis as proenzymes (pro-MMP), some may also be stored within cells (e.g. MMP-9 in neutrophil granules), and others are bound to cell surface membranes (e.g. MT1-MMP). The pro-MMPs are activated by proteolytic cleavage in the extracellular space, where MMP-3 appears to be a key player by activating other MMPs in this manner (van Meurs et al. 1999, Dollery and Libby 2006). Baseline production of MMPs is low. Synthesis of MMPs is induced by a broad range of stimuli including cytokines (interleukin-1, -4, -6, and -10, and tumor necrosis factor-α), growth factors, EMMPRIN (extracellular MMP inducer) and cell-cell or cell-matrix interactions, which all signal through intracellular pathways such as the mitogen-activated protein kinase pathway (Kossakowska et al. 1999, Meller et al. 2000, Hidalgo and Eckhardt 2001, Corps et al. 2004, Gabison et al. 2005).

The composition of the ECM depends on the balance between tissue formation and breakdown (Figure 1). Because the latter is mediated mostly by MMPs, strict regulation of MMP production and activity is an essential part of ECM homeostasis. This regulation takes place at the levels of gene

---

**Table 1. The MMP family.** Compiled from Hidalgo and Eckhardt (2001), Chakraborti et al. (2003), Pavlaki and Zucker (2003), Visse and Nagase (2003), Illman et al. (2006), Nagase et al. (2006), Pearce and Shively (2006). Stromelysin 3 is grouped with “other MMPs” since the enzyme has different properties from other stromelysins. Among the collagenous substrates for collagenases, bold numbers for collagens indicate strongest enzymatic activity.

| Group | MMP | Collagenous substrates | Noncollagenous ECM substrates | Nonstructural ECM component substrates |
|-------|-----|------------------------|-------------------------------|----------------------------------------|
| **Collagenases** | | | | |
| Collagenase 1 | MMP-1 | collagens I, II, III, VII, VIII, X, Xi, gelatins | proteoglycans, fibronectin, entactin, laminin, tenascin, vitronectin | α-1-antiprotease, pro-TNFα |
| Collagenase 2 | MMP-8 | collagens I, II, III, V, VII, VIII, X | fibronectin, laminin, proteoglycans | ADAMTS-1, pro-MMP-8 |
| Collagenase 3 | MMP-13 | collagens I, II, III, IV, V, VII, IX, X, gelatins | proteoglycans, fibronectin, laminin, tenascin | fibrinogen, proMMP-9 and -13 |
| **Gelatinases** | | | | |
| Gelatinase A | MMP-2 | gelatins, collagens I, II, III, IV, VII, X | laminin, elastin, fibronectin, proteoglycans | pro-MMPs -9 and -13, α-1-antiprotease, IGFBPs, IL-1β, TGFβ |
| Gelatinase B | MMP-9 | gelatins, collagens IV, V, VII, X, Xi | laminin, elastin, fibronectin, proteoglycans | α-1-antiprotease, CXCL5, IL-1β, TGFβ, plasminogen |
| **Stromelysins** | | | | |
| Stromelysin 1 | MMP-3 | collagens IV, V, VII, IX, X, XI, gelatins | laminin, fibronectin, elastin, proteoglycans | pro-MMPs, pro-TNFα, E-cadherin, L-selectin, fibronogen, pro-MMPs |
| Stromelysin 2 | MMP-10 | collagens I, II, III, IV, V, IX, X, gelatins | laminins, proteoglycans | |
| **Matrilysins** | | | | |
| Matrilyn 1 | MMP-7 | gelatins, collagens I and IV | laminin, elastin, fibronectin, proteoglycans, tenascin | pro-MMPs, pro-α-defensin, pro-TNFα, E-cadherin |
| Matrilyn 2 | MMP-26 | as above | as above | as above |
| **Membrane-type (MT) MMPs** | | | | |
| MT1-MMP | MMP-14 | gelatin, collagens I, II, III | proteoglycans, fibronectin, tenascin, fibrinogen | Pro-MMP-2 and -13 |
| MT2-MMP | MMP-15 | gelatins, collagen III | fibronectin | Pro-MMP-2 |
| MT3-MMP | MMP-16 | | | Pro-MMP-2 |
| MT4-MMP | MMP-17 | | | Pro-MMP-2 |
| MT5-MMP | MMP-24 | gelatin | fibronectin | |
| MT6-MMP | MMP-25 | | | |
| **Other MMPs** | | | | |
| Stromelysin 3 | MMP-11 | collagens, gelatins | fibronectin elastin, proteoglycans components of basement membranes | α-1-antiprotease, serpins |
| Metalloelastase | MMP-12 | | | plasminogen |
| RASI | MMP-19 | | | |
| Enamelysin | MMP-20 | | | |
| Enamelysin | MMP-21 | gelatin | | |
| Epilysin | MMP-28 | | | Pro-TGFβ |

ADAMTS: a disintegrin and metalloproteinase with thrombospondin motifs; ECM: extracellular matrix; TGF: transforming growth factor; TNF: tumor necrosis factor; RASI: rheumatoid arthritis synovial inflammation; IGFBP: insulin growth factor binding protein; CXCL: CXC chemokine ligand.
transcription, pro-MMP activation, and inhibition of active enzymes (Figure 2).

There are 4 TIMPs, which reversibly inhibit all MMPs by 1:1 interaction with the zinc-binding site (Hidalgo and Eckhardt 2001). TIMP-1, -2, and -4 are found in the tissues as well as in the circulation, while TIMP-3 is sequestered in the ECM (Baker et al. 2002). The specificity of TIMPs for individual MMPs is quite overlapping, although MT-MMPs appear to be resistant to TIMP-1 (Baker et al. 2002, Dollery and Libby 2006). TIMPs have several functions besides MMP inhibition, such as their roles in regulation of angiogenesis and cellular proliferation (Chirco et al. 2006). Additional endogenous inhibitors of MMPs include the soluble α-1-antitrypsin and α-2-macroglobulin (Nagase et al. 2006), as well as cell membrane-linked MMP inhibitors (Baker et al. 2002).

MMPs appear to have prominent roles in several diseases with a component of tissue destruction, such as osteoarthritis and rheumatoid arthritis (Bramano et al. 2004). It should be mentioned, however, that the view of MMPs as being solely tissue-degrading enzymes is somewhat oversimplified. This has been exemplified in a model of Porphyromonas gingivalis-induced periodontitis, where MMP-8 knockout mice suffered a more extensive alveolar bone loss than wild-type mice (Kuula et al. 2009). These findings may be explained by data showing that MMPs can exert anti-inflammatory actions, possibly by processing of anti-inflammatory cytokines and chemokines (Owen et al. 2004, Gueders et al. 2005). The variable roles of MMPs are further illustrated by data from a case study on patients with a phenotype of multicentric osteolysis with fragile skin, joint laxity, and hernias). Thirdly, ADAMTS-13 cleaves the von Willebrand factor involved in coagulation, and mutations in this protein are coupled to thrombotic thrombocytopenic purpura. There is a fourth group of ADAMTS (-6, -7, -10, -12, -16, -17, -18, and -19) can be roughly described as having proteoglycanolytic action, although there are other reported functions such as regulation of angiogenesis and degradation of other proteins for some of the group members. ADAMTS-2, -3, and -14 constitute the second group and they have anabolic function, acting as procollagen N-propeptidases for collagen types I, II, and III. Their importance in physiology is illustrated by the finding of an ADAMTS-2 mutation in Ehlers-Danlos syndrome type VII C (a condition with fragile skin, joint laxity, and hernias). Thirdly, ADAMTS-13 cleaves the von Willebrand factor involved in coagulation, and mutations in this protein are coupled to thrombotic thrombocytopenic purpura. There is a fourth group of ADAMTS (-6, -7, -10, -12, -16, -17, -18, and -19) with largely unknown function (Jones and Riley 2005). TIMP-3 is the main TIMP to have any inhibitory activity against some of the ADAMs and ADAMTS (Mochizuki and Okada 2007).
MMP inhibitors. There are several types of MMP inhibitors, including tetracycline antibiotics. If proven effective for any anti-MMP indication, these already approved drugs might be quickly brought into clinical practice.

There are several classes of pharmacological MMP inhibitors. The most common mechanism of action is binding to the zinc site of the MMP enzyme, thereby blocking its activity. The tetracycline antibiotics have several important non-antibiotic mechanisms (Figure 3) (Tamargo et al. 1991, Amin et al. 1996, Kloppenburg et al. 1996, Golub et al. 1998, Yrjanheikki et al. 1999, Lee et al. 2004, Sapadin and Fleischmajer 2006). Doxycycline is considered to be the most potent MMP inhibitor among the tetracyclines, and shows a broad spectrum by inhibiting MMPs -1, -2, -7, -8, -9, -12, and -13, although activity against the entire MMP family has not been determined (Golub et al. 1998, Peterson 2004). Besides zinc-binding, tetracyclines also inhibit MMPs at the gene expression level and by reducing activation via the inflammatory cascade and through reactive oxygen species.

Chemically modified tetracyclines have been developed to avoid unwanted effects on the endogenous microbial flora while retaining the MMP-inhibitory action. Effects on the microbial flora can also be avoided by administering “low-dose” doxycycline, i.e. 20 mg twice a day instead of the standard dose of 100 mg twice a day. In this way, doxycycline still retains its MMP-inhibitory efficacy (Emingil et al. 2004, O’Dell et al. 2006) but has no effect on the microbial flora of the vagina or the gut (Walker et al. 2005).

Synthetic MMP inhibitors constitute a large heterogeneous group of compounds, which have been modified to increase inhibitory potency and to produce increased specificity against particular MMPs (Hu et al. 2007). Bisphosphonates, known inhibitors of osteoclastic bone resorption, also have potent MMP-inhibitory properties, probably through cation-chelation of zinc (Hidalgo and Eckhardt 2001, Heikkila et al. 2002).

Proteinases in soft tissues

Tendon disease. Tendon degeneration and rupture is largely mediated by MMPs. Inhibition may become a therapeutic alternative.

The typical histopathological finding in painful tendinopathy is degeneration, i.e. disorganized ECM, variation in the density of tendon cells ranging from hyper- to hypocellular-ity, and increase in vascularity (Riley 2004, 2008, Rees et al. 2006). Several reports have indicated that excessive matrix degradation has a role in the etiopathogenesis of painful tendinopathy and tendon rupture (Table 1) (Riley 2004, de Mos et al. 2007). One pilot study has also suggested that there is a systemic disturbance in the regulation of MMPs and TIMPs in tendon rupture (Pasternak et al. 2008b). The impact of systemic factors is emphasized by a study showing an association between variants of the MMP-3 gene and painful Achilles tendinopathy (Raleigh et al. 2009). Painful tendinopathy and tendon rupture are probably somewhat distinct entities, since degeneration in ruptured tendons is generally painless but more severe than in painful tendinopathy (Tallon et al. 2001) and there are differences in the expression of structural proteins and proteolytic enzymes (Corps et al. 2006, Jones et al. 2006), as well as genetic differences (Mokone et al. 2006, Raleigh et al. 2009).

Enzyme inhibitors have not been subject to any extensive evaluation in the treatment of tendinopathy. 2 small trials with peritendinous injections of aprotinin, a general protease inhibitor, have been conducted and showed some benefit for patellar and Achilles tendinopathy (Magra and Maffulli 2005). Further support for its efficacy comes from a large case series on chronic tendinopathy (Orchard et al. 2008). However, in a small randomized trial on Achilles tendinopathy, treatment with aprotinin as an adjunct to eccentric training was not found to be better than placebo (Brown et al. 2006).

Pain in tendinopathy might be mediated by the neurotransmitter substance P (SP) (Alfredson 2005, Schubert et al. 2005). Interestingly, SP is capable of regulating the gene expression of MMPs and TIMPs in fibroblasts (Cury et al. 2008), which may link SP to the altered regulation profile of MMPs and TIMPs observed in tendinopathy. SP is also involved in repair processes and, when administered exogenously, appears to enhance proliferation of fibroblasts and tendon healing (Ackermann et al. 2003, Bursssens et al. 2005, Steyaert et al. 2006). Furthermore, patients who develop shoulder stiffness after arthroscopic rotator cuff repair have been found to have markedly elevated plasma SP levels as compared to patients with a good postoperative outcome (Franceschi et al. 2008).

The Achilles tendon has served as the model tendinopathy for etiopathologic studies, and will probably serve as a model tendinopathy for treatment studies. However, the molecular profiles of tendinopathy in other regions should be determined.
since supraspinatus tendinopathy, for example, may be a distinct entity as compared to Achilles tendon disease (Lo et al. 2004). Thus, detailed molecular studies are required in order to be able to tailor specific mechanism-based therapy.

**Tendon healing.** General inhibition of MMPs impairs tendon healing, but more selective treatment might possibly have a positive effect. Sutures coated with MMP inhibitors have a better grip.

Only a few studies have dealt with the role of MMPs in tendon healing. Based on mRNA data from unloaded healing rat flexor tendons, it has been suggested that MMP-9 and MMP-13 participate only in tissue degradation during the early phase of healing, while MMP-2, -3, and -14 participate both in tissue degradation and in later remodeling (Oshiro et al. 2003). These data must be confirmed—especially in view of the large differences observed in mechanical properties and expression of growth factor genes, depending on the loading status of the tendon during healing (Virchenko and Aspenberg 2006, Eliasson et al. 2008). An experimental study showed that systemic treatment with the MMP inhibitor doxycycline led to weakening of rat Achilles tendons during healing, which suggests that MMPs are important for tendon healing (Pasternak et al. 2006). However, the results do not rule out the possibility that MMP inhibitors could be used to enhance tendon healing, since studies of specific MMPs that act during tendon healing may identify those that are deleterious to healing, thus allowing treatment with inhibitors specific for certain subspecies of MMPs. Results from a pilot study suggest that the target MMP may be MMP-7, since there was a strong inverse correlation between levels of this proteinase and tendon strength during healing in humans (Pasternak et al. 2008b). MMP-13 could be another target; it has been implicated in tendon degradation caused by stress-deprivation (Arnoczky et al. 2007) and its expression is strongly upregulated in rotator cuff rupture (Lo et al. 2004).

Several experimental studies have shown that the mechanical properties of tendon can be manipulated by MMP inhibitors. An ex vivo rat tail tendon model showed that weakening of tendon induced by unloading could be inhibited by the MMP inhibitors GM 6001 and doxycycline (Arnoczky et al. 2007). Furthermore, a rabbit model of anterior cruciate ligament reconstruction showed that the endogenous MMP inhibitor \( \alpha \)-2-macroglobulin, injected intra-articularly, improved mechanical and histological characteristics of tendon to bone healing (Demirag et al. 2005).

Experimental studies have shown that the strength of the suture construct in tendons becomes transiently reduced in the immediate postoperative period after surgical repair of tendon rupture (Wada et al. 2001, Yildirim et al. 2006). A degradative process, mediated by MMPs, is thought to occur in the direct vicinity of the sutures, leading to weakening of tendon tissue around the suture (McDowell et al. 2002). This is thought to facilitate the suture to cut through the tendon when exposed to tensile stress, i.e. during mobilization. Inhibition of MMPs could thus help to improve tendon suture-holding capacity. Based on this idea, it has been shown that doxycycline-coated sutures can improve early tendon suture-holding capacity in a rat model (Pasternak et al. 2007).

**Frozen shoulder.** Reduced MMP activity may be involved in the pathogenesis of frozen shoulder.

In the late 1990s, several cancer trials with MMP inhibitors were conducted. In one study, frozen shoulder and/or Dupuytren’s-like contracture was reported in 6 of 12 gastric

---

**Table 2. mRNA expression and enzyme activity (or levels of active enzyme) of MMPs, TIMPs, ADAM, and ADAMTS in human tendon disease. Only proteins that showed statistically significant differences between groups are shown. Note that there are some contrasting results due to differences between studies. Data from Riley et al. (2002), Alfredson et al. (2003), Lo et al. (2004), Voloshin et al. (2005), Jones et al. (2006), de Mos et al. (2007), Corps et al. (2008), Karousou et al. (2008), and de Mos et al. (2009)**

|                          | Elevated          | Decreased        |
|--------------------------|-------------------|------------------|
| **Painful Achilles tendinopathy compared to control** | Gene expression   | Activity         |
|                          | MMP-2, -11, -13, -16, -23 ADAM-12 ADAMTS-2, -3 | MMP-3, -10, -12, -27 TIMP-3 ADAMTS-5 |
|                          | **Activity**      | **MMP-3**        | n.a.             |
| **Ruptured Achilles tendon compared to control** | Gene expression   | Activity         |
|                          | MMP-1, -2, -9, -11, -14, -17, -19, -25 TIMP-1 ADAM-8, -12 ADAMTS-4 | MMP-3, -7, -24, -28 TIMP-2, -3, -4 ADAMTS-7, -13 |
|                          | **Activity**      | **MMP-2 and 9 ADAMTS-4** | n.a.             |
| **Ruptured rotator cuff compared to control** | Gene expression   | Activity         |
|                          | MMP-13           | MMP-3, -7, -24, -28 TIMP-2, -3, -4 ADAMTS-7, -13 |
|                          | **Activity**      | **MMP-2**        |                 |

n.a.: not applicable.
cancer patients treated with the MMP inhibitor marimastat (Hutchinson et al. 1998). Musculoskeletal side effects were later confirmed by reports of adverse effects from large trials evaluating MMP inhibitors for various indications. The group of side effects included frozen shoulder, Dupuytren’s-like contracture, and arthralgias, and it was named the musculoskeletal syndrome (MSS). Although the exact mechanism is unknown, MSS is attributed either to the inhibition of too wide a spectrum of MMPs, or to unavoidable side effects of inhibiting the specifically targeted MMPs (Peterson 2004). Side effects from MMP inhibitors appear to be dose-dependent and develop only in patients on long-term therapy. The latter indicates that MSS will not be a problem for potential short-term indications, e.g. perioperative treatment. Furthermore, MSS is not a feature of every MMP inhibitor and has not been reported with tetracyclines. In addition, subspecies-selective MMP inhibitors may not have these side effects.

A non-quantitative gene expression study on frozen shoulder tissue showed an absence of MMP-14 as well as reduced expression of MMP-1, indicating that reduced collagenolysis may have a role in the pathogenesis of this disease (Bunker et al. 2000). Further studies using quantitative PCR and protein detection techniques will be needed in order to obtain a better understanding of this disease. Future therapy could possibly be directed at inhibition of the TIMPs, preferably by a local drug delivery approach.

**Dupuytren’s disease.** This disease has a complex regulation profile of metalloproteinases and inhibitors. TIMP-1 may be the most important. Local injection of MMPs has shown therapeutic promise.

Dupuytren’s disease of the hand, which is common in northern Europe, is a fibroproliferative disease of the palmar fascia. Myofibroblasts are responsible for contraction of the tissue, leading to hand dysfunction. Nodules in Dupuytren’s disease represent active disease with myofibroblast proliferation, while cords are typical of late-stage disease. A comprehensive gene expression profiling of MMPs, TIMPs, and ADAMTS using tissue samples from nodules and cords of patients with Dupuytren’s disease and control palmar fascia samples from patients with carpal tunnel disease revealed a complex regulation profile with distinctive patterns for active and late-stage disease (Table 3) (Johnston et al. 2007). Based on these findings, the authors suggested that contraction and fibrosis in Dupuytren’s disease may result from several mechanisms including ADAMTS-14-mediated promotion of collagen synthesis, TIMP-1 inhibition of collagenolytic activity, and MMP-14-mediated pericellular collagenolysis, allowing contraction. Interestingly, levels of some of the MMPs and ADAMTS were found to show a correlation with recurrence more than a year later (Johnston et al. 2008), suggesting their possible clinical use as predictive markers. In addition, it was shown that the broad-spectrum MMP inhibitor GM6001 (ilomastat) reduced Dupuytren’s disease fibroblast-mediated contraction in an in vitro model (Townley et al. 2008).

One further study has highlighted the key role of TIMP-1 in the pathogenesis of fibrotic changes in Dupuytren’s disease (Ulrich et al. 2003). The investigators showed elevation of TIMP-1 in the serum of patients with active Dupuytren’s disease as compared to carpal tunnel syndrome controls, whereas the levels were similar between patients with inactive late-stage disease and controls. There was also a shift in the systemic MMP-TIMP balance. Detection of these changes in blood samples illustrates the important role of TIMP-1. In view of the strong hereditary component and a predilection for men in Dupuytren’s disease, it is interesting to note that TIMP-1 is located on the X-chromosome. One approach to address this issue would be to investigate whether single nucleotide polymorphisms and other genetic variation in, for example TIMP-1, might explain some of the familial predisposition to Dupuytren’s disease.

In view of TIMP-1 being an important mediator in the pathogenesis of Dupuytren’s disease, pharmacological target-
ing of this protein has been suggested as a possible therapy (Johnston et al. 2007). In another approach to non-surgical therapy, the effect of collagenase injections has been investigated in a double-blind randomized placebo-controlled trial of 35 patients with Dupuytren’s disease (Badalamente and Hurst 2007). Improvement was seen in 21 of 23 patients treated with up to 3 injections of collagenase, as compared to none of the patients treated with placebo. Although there are safety issues because of frequent adverse events, these results are promising and merit further investigation.

Disorders of the spine. Metalloproteinases are dysregulated in disc disease, and idiopathic scoliosis, ankylosing spondylitis, and disc disease have been connected to genetic variants of MMPs.

Degeneration of the anulus fibrosus of intervertebral discs, leading to disc herniation and sciatic pain, is thought to be mediated (at least in part) by MMP-1 and -3 (Goupille et al. 1998). Furthermore, a recent study has shown elevation of ADAMTS-1, -4, -5, and -15 in degenerated intervertebral discs, with the levels of ADAMTS-4, -5, and -15 increasing with increasing degree of degeneration (Pockert et al. 2009).

Degeneration of intervertebral discs appears to have a strong genetic component, as shown by epidemiological studies (Ala-Kokko 2002). This may be partly explained by MMP gene variants. A single nucleotide polymorphism (C to T) in the promotor region of the MMP-2 gene results in reduced transcription. Patients with lumbar disc degeneration have a higher rate of homozygosity for the CC genotype (Dong et al. 2007). Furthermore, patients with the CC genotype have more severe disc degeneration than patients with CT and TT genotypes. This suggests that patients prone to disc degeneration have a tendency to have higher transcription of the MMP-2 gene and that among patients with disc degeneration, those with higher transcription of the MMP-2 gene have more severe disease. Whether or not the CC genotype is associated with higher tissue and systemic levels of MMP-2 is, however, unknown.

There is a highly variable region within the promoter region of the MMP-3 gene, the so-called 5A/6A polymorphism. One allele has a run of 6 adenosines (6A) and the variant allele has a run of 5 adenosines (5A). It has been reported that the 5A allele has twice as much promoter activity as the 6A allele. About half of the population carries this allele. In a radiographic study of volunteers, this genotype was associated with intervertebral disc degeneration in elderly, but not young, patients (Takahashi et al. 2001). In a small study, Aulisa et al. (2007) reported an association between adolescent idiopathic scoliosis and the 5A/6A MMP-3 promoter polymorphism. The rate of having a homozygous genotype for the 5A allele of the MMP-3 promoter was found to be 3 times higher in scoliotic patients (30%) than in healthy controls (11%).

MMP-3 has also been implicated in ankylosing spondylitis. Serum MMP-3 levels were found to be twice as high in ankylosing spondylitis patients than in controls, and showed a positive correlation with disease activity (Chen et al. 2006). In addition, serum MMP-3 was found to be an independent predictor of radiographic progression 2 years later, particularly in patients with pre-existing radiographic damage (Maksymowycz et al. 2007). Circulating MMP-3 levels were also reduced by TNF-α-blocker treatment in ankylosing spondylitis, and there was a correlation between changes in MMP-3 and changes in disease activity during treatment (Maksymowycz et al. 2008).

Fracture healing. Fracture non-union is associated with altered levels of serum MMPs. Variation in the healing of other tissues appears to be related to MMPs. This may also be the case for bone fractures, indicating that there may be therapeutic possibilities.

Patients who develop non-union of long bone fractures have been found to have higher levels of pro-MMP-1 and MMP-8, and lower TIMP-1 in serum during postoperative monitoring than patients who heal normally (Henle et al. 2005). The same research group also showed suppression of serum TGF-β in patients who developed non-union (Zimmermann et al. 2005). This suggests that there may be a possibility of monitoring and predicting the outcome of healing using blood samples. In fact, there have been a few studies in other fields of research that have shown associations between MMP levels and outcome of tissue healing. Preoperative MMP-9 levels in nasal secretions were found to show an inverse correlation with quality of healing after sinus surgery (Watelet et al. 2004), while MMP-9 in wound fluid obtained at 24 hours after inguinal hernia surgery showed an inverse correlation with collagen deposition at 10 days (Agren et al. 1998). MMP-1, -2, and -9 levels in peroperative intestinal biopsies were elevated in patients who developed anastomotic wound failure after colorectal resection (Stumpf et al. 2005). MMP inhibitors have been shown to improve healing of intestinal and cutaneous wounds (Witte et al. 1998, Syk et al. 2001, Pasternak et al. 2008a). Future experimental studies will show whether there is any effect of MMP inhibitors (general and selective) on fracture healing.

Prosthetic loosening. Genetic variants of MMP regulation are related to increased risk of loosening.

The causes of aseptic loosening of hip prostheses have been debated extensively (Sundfeldt et al. 2006). Studies of the implant interface membrane tissue have shown evidence of MMP-mediated collagen breakdown (Takagi 1996) and the extracellular matrix metalloproteinase inducer (EMMPRIN), which upregulates several MMPs, has been found at elevated levels around loosened implants (Li et al. 1999). Expression of several MMPs appears to be upregulated in macrophages in vitro in response to titanium and PMMA particles (Nakashima et al. 1998). These data suggest the possibility of pharmacological intervention in patients who (begin to) develop aseptic loosening. Intriguingly, in vitro bone resorption by cells obtained from the interface membrane of patients with aseptic loosening of hip prostheses can be inhibited by doxycycline (Ong and Taylor 2003).
Finally, a single nucleotide polymorphism (SNP) in the promoter region of the MMP-1 gene has been found to be associated with aseptic loosening of hip prostheses (Malik et al. 2007). Another, smaller study found an association between different SNPs in the MMP-1 gene promoter region and aseptic loosening of hip prostheses (Godoy-Santos et al. 2009). This SNP increases the activity of the MMP-1 gene (Rutter et al. 1998), and therefore patients with this gene variant may have elevated MMP-1 production that results in excessive tissue damage. Further investigation of this SNP may provide a way of identifying patients at risk of prosthetic loosening, even before surgery.

**Joint diseases**

**Rheumatoid arthritis.** Because MMPs mediate joint destruction, MMP inhibitors are now used as therapeutics for mild rheumatoid arthritis.

MMPs have been established as major mediators of the destruction of joint cartilage and bone in rheumatoid arthritis (RA) (Tchetverikov et al. 2004, Rengel et al. 2007) and this knowledge is now about to be applied in the clinic. Circulating MMP-1 and -3 have been suggested to be promising markers of disease severity in RA (Green et al. 2003). One study in which several biomarkers were evaluated showed that baseline serum MMP-3 is a reliable predictor of radiographic progression of RA 2 years later (Young-Min et al. 2007). A functional polymorphism in the MMP-3 gene promoter, associated with elevated serum levels of MMP-3, has been linked to radiographic progression of RA in European but not in Japanese patients (Constantin et al. 2002, Mattey et al. 2004, Tsukahara et al. 2008).

Further evidence for the implication of MMPs in RA has come from treatment studies. 6 months of treatment with methotrexate of patients with newly diagnosed RA led to reduced serum levels of MMP-1, -9, -13, and TIMP-1 (Fiedorczyk et al. 2006). In another study, lefluonomide and methotrexate treatment both led to a decrease in activated MMPs in serum of patients with RA (Tchetverikov et al. 2008). Corticosteroid injections into the knee joint of patients with active RA synovitis induced suppression of serum MMP-3, but not of the MMP-1/TIMP-1 complex (Weitolf et al. 2008).

Tetracycline MMP inhibitors have been evaluated in a few randomized controlled RA trials. A study involving 66 patients with early seropositive RA evaluated doxycycline as an adjunct therapy to methotrexate. At the 2-year follow-up, the doxycycline-methotrexate combination had improved the main outcome variable (American College of Rheumatology; ACR 50%) as compared to methotrexate alone (O’Dell et al. 2006). Importantly, the positive effects were similar between the standard dose of 100 mg twice daily and 20 mg twice daily, corroborating the concept of low-dose doxycycline, i.e. that the mechanism of action is dependent on the MMP-inhibitory and anti-inflammatory actions of doxycycline rather than any possible antimicrobial effects. Benefit of another tetracycline MMP inhibitor, minocycline, has also been demonstrated in a randomized trial (O’Dell et al. 2001). There have, however, also been studies that showed no effects of tetracyclines on symptoms and progression of RA (van der Laan et al. 2001). Minocycline is currently included in the ACR guidelines as an alternative in the treatment of RA of short duration, with low disease activity and absence of poor prognostic features (Saag et al. 2008). There have been no published trials evaluating synthetic MMP inhibitors in RA. Because of the important pathophysiological roles of, for example, MMP-3 and -13 in RA, trials with selective MMP inhibitors are eagerly awaited.

When approaching the clinical use of MMP as markers of, for example, disease activity, there will be a need for standardization of sampling procedures and types of assay, as variations in levels between serum and plasma and several other factors are important for the interpretation of the results (Mannello 2008).

**Osteoarthritis.** MMP-3 levels appear to be related to prognosis. MMP inhibitor therapy has already been tried, with mixed results.

Gene expression for several of the proteolytic MMP and ADAMTS enzymes is upregulated in cartilage and synovium in patients with osteoarthritis (OA) (Davidson et al. 2006). Furthermore, there is downregulation of TIMP-1 and -4 expression in OA cartilage, suggesting an altered balance favoring proteolysis. MMP-13, the collagenase with the strongest activity against type II collagen, is thought to be one of the key metalloproteinases in OA-associated joint destruction (Takaishi et al. 2008).

MMP-3 has been evaluated as a prognostic tool in prediction of the disease course in OA. Patients with plasma MMP-3 levels in the upper tertile of the baseline distribution have been found to be more likely to suffer progression of OA over a 30-month period than patients in the lower tertile (odds ratio: 4) (Lohmander et al. 2005).

Randomized trials have shown conflicting results of MMP inhibitor treatment in OA. Doxycycline has been found to have positive effects on radiographic progression but had no effect on joint pain (Brandt et al. 2005), while PG-116800, a broad-spectrum synthetic MMP inhibitor, showed no effect in a large study (Krizeski et al. 2007).

**Septic, Borrelia-induced, and reactive arthritis.** In several types of arthritis, MMP inhibition may reduce joint destruction.

Septic arthritis often leads to rapid destruction of joint cartilage and periarticular bone. Synovial fibroblasts exposed to *Staphylococcus aureus* show strong upregulation of several MMPs (Kanangat et al. 2006). MMP-7-deficient mice developed less joint destruction in a model of septic arthritis (Gjertson et al. 2005). In another animal model, treatment with a bisphophonate together with antibiotics led to reduced bone resorption (Verdrengh et al. 2007). Although bisphosphonates inhibit resorption directly, it is possible that some of the effects may also have been mediated by the MMP-inhibitory action of...
the bisphosphonate, because addition of corticosteroids to antibiotics and alendronate further improved some of the parameters under study. Furthermore, dexamethasone was shown to reduce duration of symptoms and long-term joint dysfunction in a randomized placebo-controlled study of 123 children with septic arthritis (Oddo et al. 2003). Being strongly anti-inflammatory and known to inhibit several mediators, including, for example, MMP-9 (Liu et al. 2008), corticosteroids require further study in septic arthritis. Although not uncontroversial, if effective, they could revolutionize the treatment of septic arthritis.

Investigation of Borrelia arthritis has shown the presence of several MMPs and the aggrecanase ADAMTS-4 in the joint fluid of arthritis patients and in cartilage explants infected with Borrelia (Hu et al. 2001; Behera et al. 2006). These studies also showed that the MMP inhibitor batimastat reduces glucosaminoglycan and collagen degradation in cartilage explants infected with Borrelia. Based on its antimicrobial effect, doxycycline is already in widespread clinical use for Borrelia arthritis. In view of the MMP-inhibitory action of doxycycline, it would be interesting to compare the joint-sparing effect of doxycycline with that of other antibiotics in use for Borrelia arthritis. In reactive arthritis, however, randomized controlled trials have so far not shown any positive effects of tetracyclines (Lauhio et al. 1991; Smieja et al. 2001).

Conclusion

MMPs are important mediators of connective tissue breakdown. They constitute promising pharmacological targets for clinical applications in orthopedics, rheumatology, and primary care. Furthermore, MMPs and related proteins may have a diagnostic role in prediction of the outcome of disease processes and healing.

BP did all of the reading and most of the writing. PA served as editor, supporter, and discussion partner.

BP and PA are co-inventors of a patented method for the coating of sutures with pharmacological agents, e.g. with MMP inhibitors.

Ackermann P W, Li J, Lundeberg T, Kreicbergs A. Neuronal plasticity in relation to nociception and healing of rat achilles tendon. J Orthop Res 2003; 21 (3): 432-41.

Ageren M S, Jorgensen L N, Andersen M, Viljanto J, Gottrup F. Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans. Br J Surg. 1998; 85 (1): 68-71.

Ala-Kokko L. Genetic risk factors for lumbar disc disease. Ann Med 2002; 34 (1): 42-7.

Alfredson H. The chronic painful Achilles and patellar tendon: research on basic biology and treatment. Scand J Med Sci Sports 2005; 15 (4): 252-9.

Alfredson H, Lorentzon M, Backman S, Backman A, Lerner U H, cDNA-arrays and real-time quantitative PCR techniques in the investigation of chronic Achilles tendinosis. J Orthop Res 2003; 21 (6): 970-5.

Amin A R, Attur M G, Thakker G D, Patel P D, Vyas P R, Patel R N, Patel I R, Abramson S B. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A. 1996; 93 (24): 14014-9.

Arnoczy S P, Lavagnino M, Egerbacher M, Caballero O, Gardner K. Matrix metalloproteinase inhibitors prevent a decrease in the mechanical properties of stress-deprived tendons: an in vitro experimental study. Am J Sports Med 2007; 35 (5): 763-9.

Aulisio L, Papaleo P, Pola E, Angelini F, Aulisia A G, Tamburrrelli F C, Pola P, Logroscino C A. Association between IL-6 and MMP-3 gene polymorphisms and adolescent idiopathic scoliosis: a case-control study. Spine 2007; 32 (24): 2700-2.

Badalamente M A, Hurst L C. Efficacy and safety of injectable mixed collag enase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg (Am) 2007; 32 (6): 767-74.

Baker A H, Edwards D R, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115 (Pt 19): 3719-27.

Behera A K, Hildebrand E, Szafranski J, Hung H H, Grodzinsky A, Lafyatis R, Koch A E, Kalshf Perides O, Steere A C, Hu L T. Role of aggrecanase 1 in Lyme arthritis. Arthritis Rheum. 2006; 54 (10): 3319-29.

Bramono D S, Richmond J C, Weitzel P P, Kaplan D L, Altman G H, Matrix metalloproteinases and their clinical applications in orthopedics. Clin Orthop 2004; (428): 272-85.

Brandt K D, Mazzucca S A, Katz B P, Lane K A, Backwelter K A, Yocum D E, Wolfe F, Schnitzer T J, Moreland L W, Manzi S, Bradly J D, Sharma L, Odds D C, V. Hugenberg S T, Heck L W. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005; 52 (7): 2015-25.

Brown R, Orchard J, Kichington M, Hooper A, Nalder G. Aprotinin in the management of Achilles tendinopathy: a randomised controlled trial. Br J Sports Med 2006; 40 (3): 273-9.

Bunker T D, Reilly J, Baird K S, Hambleton D L. Expression of growth factors, cytokines and matrix metalloproteinases in frozen shoulder. J Bone Joint Surg (Br) 2000; 82 (5): 768-73.

Bursens P, Steyaert A, Forsyth T, van Ovost E J, Depaepe Y, Verdonk P. Badalamente M A, Hurst L C. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg (Am) 2007; 32 (6): 767-74.

Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253 (1-2): 269-85.

Chen C H, Lin K C, Yu D T, Yang C, Huang F, Chen H A, Liang T H, Liao T H, Tsai C Y, Wei J C, Chou C T. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis. MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatol ogy (Oxford) 2006; 45 (4): 414-20.

Chirico R, Liu X W, Jung K K, Kim H R. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006; 25 (1): 99-113.

Constantin A, Lauwers-Cances V, Navaux F, Abbal M, van Meerwijk J, Mazieres B, Cambon-Thomsen A, Cantagrel A. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: Association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum. 2002; 46 (7): 1754-62.

Corps A N, Curry V A, Buttle D J, Hazleman B L, Riley G P. Inhibition of interleukin-1beta-stimulated collagenase and stromelysin expression in human tendon fibroblasts by epigallocatechin gallate ester. Matrix Biol 2004; 23 (3): 163-9.

Corps A N, Robinson A H, Movin T, Costa M L, Hazleman B L, Riley G P. Increased expression of aggrecan and biglycan mRNA in Achilles tendinopathy. Rheumatology 2006; 45 (3): 291-4.

Corps A N, Jones G C, Harrall R L, Curry V A, Hazleman B L, Riley G P. The regulation of aggrecanase ADAMTS-4 expression in human Achilles tendon and tendon-derived cells. Matrix Biol 2008; 27 (5): 393-401.
Cury P R, Canavez F, de Araujo V C, Furuse C, de Araujo N S. Substance P regulates the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in cultured human gingival fibroblasts. J Periodontal Res 2008; 43 (3): 255-60.

Davidson R K, Waters J G, Kevorkian L, Darrah C, Cooper A, Donnell S T, Clark I M. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther 2006; 8 (4): R124.

de Mos M, van El B, deGroot J, Jahu H, van Schie H T, van Arkel E R, Tol H, Heijboer R, van Osch G J, Verhaar J A. Achilles tendonitis: changes in biochemical composition and collagen turnover rate. Am J Sports Med 2007; 35 (9): 1549-56.

de Mos M, Joosten L A, Oppers-Walgreen B, van Schie J T, Jahu H, van Osch G J, Verhaar J A. Tendon degeneration is not mediated by regulation of Toll-like receptors 2 and 4 in human tenocytes. J Orthop Res 2009; 27 (8): 1043-7.

Demirag B, Sarisozen B, Ozier O, Kaplan T, Ozturk C. Enhancement of tendon-bone healing of anterior cruciate ligament grafts by blockage of matrix metalloproteinases. J Bone Joint Surg (Am) 2005; 87 (11): 2401-10.

Dollery C M, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69 (3): 625-35.

Dong D M, Yao M, Liu B, Sun C Y, Jiang Y Q, Wang Y S. Association between the -1306C/T polymorphism of matrix metalloproteinase-2 gene and lumbar disc disease in Chinese young adults. Eur Spine J 2007; 16 (11): 1598-65.

Eliasson P, Fahlgren A, Aspenberg P. Mechanical load and BMP signaling during tendon repair: a role for follistatin? Clin Orthop 2008; (466): 1592-7.

Emingil G, Atilla G, Sorsa T, Luoto H, Kirilmaz L, Baylas H. The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol 2004; 75 (1): 106-15.

Fiedorczyk M, Klumiuk P A, Sierakowski S, Gindzienska-Sieskiewicz E, Chwieccko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol 2006; 33 (8): 1523-9.

Foos M J, Hickox J R, Mansour P G, Slatterbeck J R, Mansour P G. Expression of matrix metalloprotease and tissue inhibitor of metalloprotease genes in human anterior cruciate ligament. J Orthop Res 2001; 19 (4): 642-9.

Franceschi F, Longo U G, Ruzzini L, Morini S, Battistoni F, Dicouzgo G, Maffulli N, Denaro V. Circulating substance P levels and shoulder joint contracture after arthroscopic repair of the rotator cuff. Br J Sports Med 2008; 42 (9): 742-5.

Gabison E E, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005; 87 (9): 742-5.

Gajarski M M, Hazleman B L, Riley G P, Expression of metalloproteinase and tissue inhibitors of metalloproteinases in normal and degenerate human achilles tendons. Arthritis Rheum 2006; 54 (3): 832-42.

Kanangat S, Postlethwaite A, Hasty K, Kang A, Smeltzer M, Appling W, Schaberg G. Induction of multiple matrix metalloproteinases in human dermal and synovial fibroblasts by Staphylococcus aureus: implications in the pathogenesis of septic arthritis and other soft tissue infections. Arthritis Res Ther 2006; 8 (6): R176.

Karouso E, Ronga M, Viggeti D, Assa J, Maaluffi N, Collagens, proteoglycans, matrix metalloproteinases, TIMPs in human achilles tendon rupture. Clin Orthop 2008; (466): 1577-82.

Kloppenburg M, Brinkman B M, de Rooij-Dijk H H, Milenburg A M, Daha M R, Breedveld F C, Dijkmans B A, Verweij C. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother 1996; 40 (4): 934-40.

Kossakowska A E, Edwards D R, Prusinkiewicz C, Zhang M C, Quo D, Urbanski S J, Grogan T, Mareczko L A, Janowska-Wieczorek A, Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase in normal and non-Hodgkin’s lymphomas. Blood 1999; 94 (6): 2080-9.

Krzeski P, Buckland-Wright C, Bulint G, Cline G A, Stoner K, Lyon R, Bear J, Aronstein W S, Spector T D. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007; 9 (5): R109.

Kuula H, Salo T, Pirilä E, Tuomainen A M, Jauhiainen M, Uitto V J, Tjaderhane L, Pussinen P J, Sorsa T. Local and systemic responses in matrix metalloproteinase-8-deficient mice during Porphyromonas gingivalis-induced periodontitis. Infect Immun 2009; 77 (2): 850-9.

Lauhio A, Leirisalo-Heikkinen A, Kuukka H, Salo T, Pirilä E, Tuomainen A M, Jauhiainen M, Uitto V J, Tjaderhane L, Pussinen P J, Sorsa T. Local and systemic responses in matrix metalloproteinase-8-deficient mice during Porphyromonas gingivalis-induced periodontitis. Infect Immun 2009; 77 (2): 850-9.
Lee C Z, Xu B, Hashimoto T, McCulloch C E, Yang Y, Young W L. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004; 35 (7): 1715-9.

Li T F, Santavitva S, Virtanen I, Kononen M, Takagi M, Konttinen Y T. Increased expression of EMMPRIN in the tissue around loosened hip prostheses. Acta Orthop Scand 1999; 70 (5): 446-51.

Liu X, Han Q, Sun R, Li Z. Dexamethasone regulation of matrix metalloproteinase expression in experimental pneumococcal meningitis. Brain Res 2008; 1207: 237-43.

Lo I K, Marchuk L L, Hollinshead R, Hart D A, Frank C B. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase mRNA levels are specifically altered in torn rotator cuff tendons. Am J Sports Med 2004; 32 (5): 1223-9.

Lohmander L S, Brandt K D, Mazzuca S A, Katz B P, Larsonson S, Struggles A, Lane K A. Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum 2005; 52 (10): 3160-7.

Magra M, Maffulli N. Matrix metalloproteases: a role in overuse tendinopathies. Br J Sports Med 2005; 39 (11): 789-91.

Maksymowych W P, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole A R, Wang N, van der Heijde D. Serum matrix metalloproteinase-3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56 (6): 1846-53.

Maksymowych W P, Rahman P, Shojania K, Olszynski W P, Thomson G T, Ballal S, Wong R L, Inman R D. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008; 35 (10): 2030-7.

Malik M H, Jury F, Bayat A, Ollier W E, Kay P R. Genetic susceptibility to total hip arthroplasty failure: a preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor. Ann Rheum Dis 2007; 66 (8): 1116-20.

Mandal M, Mandal A, Das S, Chakraborti T, Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem 2003; 252 (1-2): 305-29.

Mannello F. Serum or plasma samples? The “Cinderella” role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic truthness and leading to misinterpretation. Artroschler Thromb Vasc Biol 2008; 28 (4): 611-4.

Martignetti J A, Aqeel A A, Sewairi W A, Boumah C E, Kambouris M, Mayouf J L. Introduction of the tensile properties and histologic/biochemical changes in normal and Achilles tendon pathology. Scand J Med Sci Sports 2006; 16 (1): 19-26.

Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69 (3): 562-73.

Nakashima Y, Sun D H, Maloney W J, Goodman S B, Scharman D J, Smith R L. Induction of matrix metalloproteinase expression in human macrophages by orthopaedic particulate debris in vitro. J Bone Joint Surg (Br) 1998; 80 (4): 694-700.

O’Dell J R, Blakely K W, Malek A J, Eckhoff P J, Leff R D, Wees S J, Sens K M, Fernandez A M, Palmer W R, Klassen L W, Paulsen G A, Haire C E, Moore G F. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001; 44 (10): 2235-41.

O’Dell J R, Elliott J R, Malek J A, Mikuls T R, Weaver C A, Glickstein S, Blakley K M, Hausch R, Leff R D. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum 2006; 54 (2): 621-7.

Ong S M, Taylor G J. Doxycycline inhibits bone resorption by human interface membrane cells from aseptically loose hip replacements. J Bone Joint Surg (Br) 2003; 85 (3): 456-61.

Oshiro W, Lou I, Xing X, Tu Y, Manske R P. Flexor tendon healing in the rat: a histologic and gene expression study. J Hand Surg (Am) 2003; 28 (5): 814-23.

Owen C A, Hu Z, Lopez-Otin C, Shapiro S D. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpine. J Immunol 2004; 172 (12): 7791-803.

Pasternak B, Fellenius M, Aspenberg P. Doxycycline impairs tendon repair in rats. Acta Orthop Belg 2006; 72 (6): 756-60.

Pasternak B, Misiors A, Askendal A, Tengvall P, Aspenberg P. Doxycycline-coated sutures improve the suture-holding capacity of the rat Achilles tendon. Acta Orthopaedica 2007; 78 (5): 680-6.

Pasternak B, Rehn M, Andersen L, Agren M S, Hoegaard A M, Tengvall P, Aspenberg P. Doxycycline-coated sutures improve mechanical strength of intestinal anastomoses. Int J Colorectal Dis 2008a; 23 (3): 271-6.

Pasternak B, Schepull T, Elaissos P, Aspenberg P. Elevation of systemic matrix metalloproteinase-2 and -7 and tissue inhibitor of metalloproteinases-2 and -7 in patients with a history of Achilles tendon rupture: pilot study. Br J Sports Med 2008b. Epub ahead of print.

Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003; 22 (2-3): 177-203.

Pearce W H, Shively V P. Abdominal aortic aneurysm as a complex multifactorial disease: interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPIs. Ann N Y Acad Sci 2006; 1085: 117-32.

Peterson J T. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9 (1): 63-79.

Pockert A J, Richardson S M, Le Maire C L, Lyon M, Deakin J A, Buttle D J, Freeman A J, Hoyland J A. Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration. Arthritis Rheum 2009; 60 (2): 482-91.

Reaigh S M, Van der Merwe L, Ribbens W J, Smith R K, Schellnus M P, Collins M. Variants within the MMP3 gene are associated with Achilles tendonopathy: Possible interaction with the COL5A1 gene. Br J Sports Med 2009; 43 (7): 514-20.

Rees J D, Wilson A M, Wolman R L. Current concepts in the management of tendon disorders. Rheumatology (Oxford) 2006; 45 (5): 508-21.

Ren X H, Peng X D, Wu X P, Liao E Y, Sun Z Q. Association between serum soluble membrane type matrix metalloproteinase-1 (MT1-MMP) levels and bone mineral density, and biochemical markers in postmenopausal women. Clin Chim Acta 2008; 390 (1-2): 44-8.
Rengel Y, Osphalt C, Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther 2007; 9 (5): 221.

Riley G. The pathogenesis of tendinopathy. A molecular perspective. Rheumatology 2004; 43 (2): 131-42.

Riley G. Tendinopathy--from basic science to treatment. Nat Clin Pract Rheumatol 2008; 4 (2): 82-9.

Riley G P, Curry V, DeGroot J, van El B, Verzijl N, Hazleman B L, Bank R A. Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology. Matrix Biol 2002; 21 (2): 185-95.

Rutter J L, Mitchell T I, Buttice G, Meyers J, Gusella J F, Ozelius L J, Brinck-erhoff C E. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58 (23): 5521-5.

Saag K G, Teng G G, Patkar N M, Anuntiyo J, Finney C, Curtis J R, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59 (6): 762-84.

Sapadin A N, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54 (2): 258-65.

Schubert T E, Weidler C, Lerch K, Hofstadter F, Straub R H. Achilles tendin-osis is associated with sprouting of substance P positive nerve fibres. Ann Rheum Dis 2005; 64 (7): 1083-6.

Smieja M, MacPherson D W, Kean W, Goldsmith C H, Sun Meja M, R匹fors P, Gretzer C. Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthopaedica 2006; 77 (1): 229-34.

Sundfeldt M, Carlsson L V, Johansson C B, Thomsen P, Gretzer C. The association of degeneration of the intervertebral disc with 5a/6a polymorphism in the promoter of the human matrix metalloproteinase-3 gene. J Bone Joint Surg (Br) 2001; 83 (4): 491-5.

Takagi M. Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Acta Orthop Scand (Suppl 271) 1996: 3-29.

Takagishi M, Haro H, Wakabayashi Y, Kawauchi T, Komori H, Shinomiya T. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the ini-tiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum 1999; 42 (10): 2074-84.

Tatele J B, Claey S, Van Cauwenberge P, Bachert C. Predictive and moni-toring value of matrix metalloproteinase-9 for healing quality after sinus surgery. Wound Repair Regen 2004; 12 (4): 412-8.

Teitost T, Larsson A, Ronnblom L. Serum levels of sex steroid hormones and matrix metalloproteinases after intra-articular glucocorticoid treatment in female patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67 (3): 422-4.

Verdregenh M, Carlsten H, Ollsson C, Tarkowski A. Addition of bisphospha-nate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis. J Orthop Res 2007; 25 (3): 304-10.

Vircenko O, Aspenberg P. How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks? Interplay between early regeneration and mechanical stimulation. Acta Orthop 2006; 77 (5): 806-12.

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92 (8): 827-39.

Witte M B, Thornton F J, Kiyama T, Efron D T, Schulz G S, Moldawer L L, Barbul A. Metalloproteinase inhibitors and wound healing: a novel enhancer of wound strength. Surgery 1998;124 (2): 464-70.

Woloshin I, Gelinas J, Maloney M D, O’Keefe J J, Bigliani L U, Blaine T A. Proinflammatory cytokines and metalloproteinases are expressed in the subacromial bursa in patients with rotator cuff disease. Arthroscopy 2005; 21 (9): 1076.

Yildirim Y, Kara H, Cabukoglu C, Esenmit T. Suture holding capacity of the Achilles tendon during the healing period: an in vivo experimental study in rabbits. Foot Ankle Int 2006; 27 (2): 121-4.

Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007; 56 (10): 3236-47.

Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007; 56 (10): 3236-47.

Zimmermann G, Henle P, Kusswetter M, Moghaddam A, Wentzensen A, Richter W, Weiss S. TGF-beta1 as a marker of delayed fracture healing. Bone 2005; 36 (5): 779-85.